E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor

被引:56
作者
Takahashi, M
Sato, T
Sagawa, T
Lu, Y
Sato, Y
Iyama, S
Yamada, Y
Fukaura, J
Takahashi, S
Miyanishi, K
Yamashita, T
Sasaki, K
Kogawa, K
Hamada, H
Kato, J
Niitsu, Y [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Internal Med 4, Sapporo, Hokkaido 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608543, Japan
[3] Sapporo Med Univ, Sch Med, Dept Mol Med, Sapporo, Hokkaido 0608543, Japan
关键词
gene therapy; hepatocellular carcinoma; alpha-fetoprotein; highly tumor-specific; replication-competent adenovirus;
D O I
10.1006/mthe.2002.0589
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Here, we constructed a recombinant replication-competent adenovirus (rRCAd; AdAFPep/Rep) that expresses both E1A-13S driven by the alpha-fetoprotein (AFP) enhancer/promoter (AFPep) lacking any silencers in the 5'-flanking region of the AFP gene, and 55K-deleted E1B driven by the cytomegalovirus (CMV) promoter. We then examined the feasibility of gene therapy utilizing this virus for AFP-producing hepatocellular carcinoma (HCC). AdAFPep/Rep lysed all the AFP-producing HCC cell lines (HuH7, HepG2, PLC/PRF/5 (P5)) examined at a multiplicity of infection (MOI) as low as 0.1 and did not lyse primary human hepatocytes (Hc) at a MOI as high as 100, indicating that the rRCAd virus can lyse AFP-producing HCC cells with a higher specificity and potency than previously reported. Furthermore, this virus was capable of complete eradication of a preestablished HuH7-cell tumor by a single intratumoral injection of 10(8) plaque-forming units (pfu) of AdAFPep/Rep. Thus, AdAFPep/Rep may be applicable for clinical use.
引用
收藏
页码:627 / 634
页数:8
相关论文
共 54 条
[1]  
Anklesaria P, 2000, CURR OPIN MOL THER, V2, P426
[2]   ADENOVIRUS TYPE-5 EARLY REGION-1B GENE-PRODUCT IS REQUIRED FOR EFFICIENT SHUTOFF OF HOST PROTEIN-SYNTHESIS [J].
BABISS, LE ;
GINSBERG, HS .
JOURNAL OF VIROLOGY, 1984, 50 (01) :202-212
[3]  
Ban N, 1996, CANCER RES, V56, P3577
[4]   Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 [J].
Barajas, M ;
Mazzolini, G ;
Genové, G ;
Bilbao, R ;
Narvaiza, I ;
Schmitz, V ;
Sangro, B ;
Melero, I ;
Qian, C ;
Prieto, J .
HEPATOLOGY, 2001, 33 (01) :52-61
[5]   ADENOVIRUS PROTEINS FROM BOTH E1B READING FRAMES ARE REQUIRED FOR TRANSFORMATION OF RODENT CELLS BY VIRAL-INFECTION AND DNA TRANSFECTION [J].
BARKER, DD ;
BERK, AJ .
VIROLOGY, 1987, 156 (01) :107-121
[6]   PACKAGING CAPACITY AND STABILITY OF HUMAN ADENOVIRUS TYPE-5 VECTORS [J].
BETT, AJ ;
PREVEC, L ;
GRAHAM, FL .
JOURNAL OF VIROLOGY, 1993, 67 (10) :5911-5921
[7]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[8]   Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination [J].
Bramson, JL ;
Hitt, M ;
Gauldie, J ;
Graham, FL .
GENE THERAPY, 1997, 4 (10) :1069-1076
[9]  
Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4
[10]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750